Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program
Three months after NewLink Genetics scrapped a combination program for its IDO pathway drug indoximod in the general rout that followed the failure of Incyte’s big IDO project for epacadostat, the biotech is nevertheless circling its wagons around a last stand effort to prove their therapy can work and make it to the market. In the process, the Iowa-based company has slashed close to a third of its staff and reorganized the C suite in the process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.